KIDDIELAND (03830) announced its interim financial performance, with a 30.57% year-on-year decrease in net profit attributable to shareholders to HK$3.85 million.
Tongyuan International (03830) released its interim performance for the six months ending on October 31, 2025. The group achieved a revenue of 129 million Hong Kong dollars, a decrease of 5.45% year-on-year. The net profit attributable to owners of the company was 3.85 million Hong Kong dollars, a decrease of 30.57% year-on-year. Earnings per share were 0.4 Hong Kong cents.
Kiddieland (03830) announced its interim performance for the 6-month period ending on October 31, 2025. The group achieved a profit of HK$129 million, a decrease of 5.45% compared to the same period last year. The net profit attributable to owners of the company was HK$3.85 million, a decrease of 30.57%, with earnings per share of 0.4 HK cents.
The announcement stated that the decrease in net profit was mainly due to a decrease in revenue and an increase in impairment losses on receivables. This was partially offset by reduced selling and distribution expenses, reduced administrative expenses, and reduced income tax expenses.
Related Articles

CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.
CHINA LESSO (02128) and Guangdong Liansu Electric have signed a parts supply agreement.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-2906 Injection Obtains Drug Clinical Trial Approval Letter.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-9539 injection, HRS-3738 tablets received the approval notice for drug clinical trials.






